Vas-Cog Journal is an official journal of the Japanese Society of Vascular cognitive impairment. Original Articles deal with either clinical or experimental investigation of the vascular cognitive impairment. The journal will also consider the publication of review articles. Manuscripts must conform to Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations) (http:// www.icmje.org/recommendations/).
Submission of a manuscript to Vas-Cog Journal implies that the article is original and that no portion (including figures or tables) is under consideration elsewhere or has been previously published in any form other than as an abstract. Previous publication includes publishing as a component of symposia, proceedings, transactions, books (or chapters), articles published by invitations or reports of any kind, as well as in electronic databases of a public nature.
Submission of a manuscript implies that, when accepted for publication, the authors agree to automatic transfer of the copyright to the Japanese Society of Vascular Cognitive Impairment. Every reproduced figure or table must have permission from the copyright holder. Authors should obtain permission in advance of manuscript submission, and clearly state that in the figure/table legend. Examples:(1) Adapted from reference no. xx with permission. (2) Reproduced with permission from xxxx, et al. Neurology 2018; 91: xx – xx.
When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional). The participants’ informed consent should be obtained and should be indicated in the text. When reporting experiments on animals, indicate whether institutional or national guidelines for the care and use of laboratory animals were followed.
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (http://www.icmje.org/), all clinical trials published in Vas-Cog Journal should be registered in a public trials registry at or before the participant recruitment. Refer to CONSORT 2010 guidelines (http://www.consort-statement.org/) for randomized clinical trials, and the STROBE statement (http://www.strobe-statement.org/) for observational studies (cohort, case-control, or cross-sectional designs).
At least the first author and corresponding author should be members of Japanese Society of Vascular Cognitive Impairment. All manuscripts must be submitted electronically through online submission system in the official web site of Japanese Society of Vascular Cognitive Impairment (http://www.plus-s-ac.com/vas-cogj/). The submitting author should upload the manuscript files in appropriate word and PDF file formats according to the instructions provided. Before completing submission, the submitting author is required to thoroughly check the PDF file.
After submission through the online submission system, the contact/submitting author should complete the “Authorship Agreement” form (http://www.plus-s-ac.com/vas-cogj/kaishi.html) with all co-authors’ signatures, and email it to the Editorial Office (email@example.com). Because any additional co-authors cannot be approved after the manuscript has been accepted, ensure that all co-authors have been properly listed during the submission process. If additional authors are included in a revised manuscript, the contact author of the manuscript is required to provide another “Authorship Agreement” form signed by the added authors as well as detailed reasons for their addition.
All manuscripts should be written in English (US spelling) and prepared according to the following specifications.
1.The main document should be typewritten by word with double spacing and include the following in general: (1) Title page, (2) Abstract, (3) Key words, (4) Text, (5) Acknowledgements, (6) References and (7) Legends for Tables and/or Figures. This word file should be sent to the office with attached converted PDF file of final published style.
2.Pages should be numbered consecutively in this sequence, beginning with the title page.
3.The title page must have the following content:
(1) Complete title of the paper; Abbreviations are not acceptable in the title.
(2) Name(s) of author(s) with highest academic degree(s); Only MD, PhD, or BSc could be included.
(3) Affiliations of all authors at the time of the study; i.e., department and institution
(4) Short title; Up to 50 characters including spaces can be used.
(5) Disclosures; Information of all COI, grants, sources of funding related to the manuscript should be declared.
(6) Name and address of the author responsible for correspondence
(7) Total word count of the manuscript
(8) Total numbers of Tables, Figures and Supplementary files
4. Abstracts in manuscript types “Original Article of Clinical or Experimental Research” should be structured, and consist of the following 3 headings:
1: Background: Rationale for study; 2. Method and Results: Brief presentation of methods and presentation of significant results; Note that both categories should be included under the one heading. 3. Conclusions: Succinct statement of data interpretation
5. Units of measurement should be SI units, except for blood pressure, which should be expressed in mmHg. Do not spell out numbers and standard units of measurement except at the beginning of sentences. Use Arabic numerals and standard abbreviations to indicate numbers and units.
6. References must be numbered consecutively as they appear in the text and be listed in the same numerical order at the end of the article. They should accord with the system used in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Only published manuscripts are accepted as references. If a reference is from a yet-to-be-published book, include ‘In Press’ as well as the anticipated year of publication. If a reference is published online only, the “D.O.I” or “URL as well as the last available date accessed” should be provided. The titles of referenced journals should be abbreviated to the style used in Index Medicus (http://www.nlm.nih.gov/tsd/serials/lji.html). All author names should be listed when referenced material has 3 or less authors; when it has 4 or more, only the first 3 authors’ names should be listed, with “et al.” at the end.
(1) Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.J Cereb Blood Flow Metab. 2009 (4):715-25.
(2) Takeda S and Morishita R. Diabetes and Alzheimer's Disease. In: Yamagishi S, editor. Diabetes and Aging-related Complications. Springer, 2018; 101-111
(3) Takeda S, Wegmann S, Cho H, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain.Nat Commun. 2015 Oct 13;6:8490. doi: 10.1038/ncomms9490
7. All figures in a manuscript are recommended to be in full color; publication in color requires page charge of JPY65,000 for one color page (see also “VI. Publication Charges”). For invited articles, publication in color is cost-free for one page and requires JPY65,000/one exceeding color page. Letters and symbols in figures should be clear and of sufficient size to be legible after reduction to the width of one column. Specify the size to be printed, if necessary.
8. Content of supplementary files will only be published in the online journal. Therefore, if a supplementary file contains References, they should be separate from those in the Main Document, and only refer to the content in the supplementary file(s). There is a size limit of 5 MB for uploaded supplementary file(s) per manuscript.
Total word count is less than 6,000 words and less than 220 words for Abstract. Number of Table and Figures are less than 8 and less than 3 supplementary figures. No limitation of numbers of references. Three to 5 Keywords and structured abstract with 3 headings are other requirements.
2.Images in Vascular Cognitive Impairmen
Images in Vascular Cognitive Impairment” should contain a novel color image with scientific impact. Note that we do not accept any case reports. The manuscript consisted of less than 400 words, 1 figure and 2 supplementary files, normally occupies 1 journal page.
3.Review Article (Invited)
“Review Article” is usually invited one upon request from the Editor-in-Chief, but we will also consider limited number of non-invited submissions. Total word count is less than 6,000 words and less than 220 words for Unstructured Abstract. Number of Table and Figures are less than 8 and less than 3 supplementary figures. No limitation of numbers of references.
“Editorial” normally occupies no more than 2 journal pages about subject manuscript should be cited Upon request from the Editor-in-Chief. Total word count is less than 1,500 words and no abstract, less than 2 Table or figures and less than 15 references.
Total word count is less than 3,000 words and less than 100 words for Unstructured Abstract. Number of Table and Figures are less than 4 and 20 references. Vas-Cog Journal encourage submission by young researches in this section.
6.Letter to the Editor” and “Author’s Reply
This is an opinion-letter to a manuscript which has been published in Vas-Cog Journal. The manuscripts must not exceed 1,000 words in length and have no more than 5 co-authors.
Authors who submit or resubmit manuscripts to the journal are required to have all of their manuscript files strictly reflect the requirements outlined here. When any part does not, we cannot start either the initial or revision review process. “Total word count” is the total number of all words appearing in the manuscript files, except for the text in Table(s) and Figure(s). Note that legends for these are included in the “Total word count”.
The submitting author should complete the online form in the submission system and have the same information included in “Disclosures” in the main document in order to disclose all authors’ relationships that could be perceived as real or apparent conflict(s) of interest. When submitting a manuscript for publication, all authors are required to disclose any financial relationship (within the past 12 months) with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has been involved in the subject matter or materials discussed in the manuscript. When a manuscript has been accepted for publication, all disclosed COI will appear in the article.
Disclosures：A (author name) serves as a consultant to Z (entity name); B’s spouse is chairman of Y; C received a research grant from X; Deceived lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.
All original manuscripts are usually evaluated by 2 reviewers assigned by the Editors.
Galley proofs of accepted manuscripts will be sent to the authors for their correction. Changes should be limited to typographical errors or errors in the presentation of data. Excessive corrections may be rejected by editors and/or be charged to the authors.
Free for publication charge in manuscript submission rules within total word count, Tables, Figures and References. JPY8,000/one exceeding page charge (JPY65,000 for one color page).
Reprints are available in a multiple of 100 copies when ordered with the return of the proofs. The approximate cost per 100 copies is JPY10,000, including color pages. Free PDF publication.
Department of Neurology
Graduate School of Medicine,
Kyoto Prefectural University of Medicine
Senior Associate Editor
Department of Clinical Gene Therapy,
Graduate School of Medicine, Osaka University
Department of Dementia and Neuropsychology,
Advanced Institute of Industrial Technology,
Tokyo Metropolitan Public University Corporation
Department of Geriatric Medicine,
Tokyo Medical University
Department of Neurology
National Cerebral and Cardiovascular Center
Department of Neurology,
Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences,
Ryuichi Morishita (Department of Clinical Gene Therapy, Osaka University)
Yoshio Ikeda (Department of Neurology, Gunma University Graduate School of Medicine)
Ken Nagata (Yokohama General Hospital)
Hiroshi Mori (Nagaoka Sutoku University)
Masahiro Akishita (Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo)
Koji Abe (National Center Hospital, National Center of Neurology and Psychiatry)
Masafumi Ihara (Department of Neurology, National Cerebral and Cardiovascular Center)
Atsushi Iwata (Department of Neurology, Tokyo Metropolitan Geriatric Medical Center Hospital)
Katsuya Urakami (Section of Environment and Health Science, Department of Biological Regulation, Faculty of Medicine, Tottori University)
Yasuyuki Ohta (Division of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine)
Kenjiro Ono (Department of Neurology & Neurobiology of Aging Kanazawa University Graduate School of Medical Sciences)
Kazuo Kitagawa (Department of Neurology. Tokyo Women 's Medical University)
Koichi Kozaki (Department of Geriatric Medicine Kyorin University School of Medicine)
Issei Komuro (Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine)
Masataka Sata (Department of Cardiovascular Medicine, Tokushima University Graduate School)
Munehisa Shimamura (Department of Neurology / Department of Health Development and Medicine, Graduate School of Medicine, Osaka University)
Takayoshi Shimohata (Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine)
Ken Shinmura (Department of General Medicine, Hyogo College of Medicine)
Kazuma Sugie (Department of Neurology, Nara Medical University School of Medicine)
Masahiko Suzuki (Department of Neurology Katsushika Medical Center The Jikei University School of Medicine)
Hidekazu Tomimoto (Department of Neurology, Mie University)
Yukihito Higashi (Department of Regeneration and Medicine,Research Center for Radiation Genome Medicine,Research Institute for Radiation Biology and Medicine, Hiroshima University)
Etsuro Matsubara (Oita University Faculty of Medicine Department of Neurology)
Miyuki Matsumura (Department of Neurology, Institute of Geriatrics,Tokyo Women's Medical University)
Toshiki Mizuno (Department of Neurology, Kyoto Prefectural University of Medicine)
Shokei Mitsuyama (Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences)
Masaru Mimura (Department of Neuropsychiatry, Keio University School of Medicine)
Masaki Mogi (Department of of Pharmacology, Ehime University Graduate School of Medicine)